These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 22966871)
1. A perspective on progress and gaps in HIV prevention science. Kiser PF; Mesquita PM; Herold BC AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1373-8. PubMed ID: 22966871 [TBL] [Abstract][Full Text] [Related]
2. Oral antiretroviral chemoprophylaxis: current status. Baeten J; Celum C Curr Opin HIV AIDS; 2012 Nov; 7(6):514-9. PubMed ID: 22964886 [TBL] [Abstract][Full Text] [Related]
3. Still a long wait for approved HIV-protective gel. Bateman C S Afr Med J; 2010 Sep; 100(9):560, 562. PubMed ID: 20822637 [No Abstract] [Full Text] [Related]
4. FDA paves the way for pre-exposure HIV prophylaxis. Holmes D Lancet; 2012 Jul; 380(9839):325. PubMed ID: 22852138 [No Abstract] [Full Text] [Related]
5. AIDS: Drugs that prevent HIV infection. Wainberg MA Nature; 2011 Jan; 469(7330):306-7. PubMed ID: 21248832 [No Abstract] [Full Text] [Related]
6. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. Hendrix CW; Chen BA; Guddera V; Hoesley C; Justman J; Nakabiito C; Salata R; Soto-Torres L; Patterson K; Minnis AM; Gandham S; Gomez K; Richardson BA; Bumpus NN PLoS One; 2013; 8(1):e55013. PubMed ID: 23383037 [TBL] [Abstract][Full Text] [Related]
7. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. Myers GM; Mayer KH AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497 [TBL] [Abstract][Full Text] [Related]
8. Preexposure prophylaxis for HIV prevention: where have we been and where are we going? Baeten JM; Haberer JE; Liu AY; Sista N J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S122-9. PubMed ID: 23764623 [TBL] [Abstract][Full Text] [Related]
9. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. Keller MJ; Madan RP; Torres NM; Fazzari MJ; Cho S; Kalyoussef S; Shust G; Mesquita PM; Louissaint N; Chen J; Cohen HW; Diament EC; Lee AC; Soto-Torres L; Hendrix CW; Herold BC PLoS One; 2011 Jan; 6(1):e16475. PubMed ID: 21283552 [TBL] [Abstract][Full Text] [Related]
10. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition. de Lastours V; Fonsart J; Burlacu R; Gourmel B; Molina JM Antimicrob Agents Chemother; 2011 Oct; 55(10):4905-7. PubMed ID: 21788466 [TBL] [Abstract][Full Text] [Related]
11. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. van der Straten A; Van Damme L; Haberer JE; Bangsberg DR AIDS; 2012 Apr; 26(7):F13-9. PubMed ID: 22333749 [TBL] [Abstract][Full Text] [Related]
12. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057 [TBL] [Abstract][Full Text] [Related]
13. Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? Goicoechea M; Best B Expert Opin Pharmacother; 2007 Feb; 8(3):371-82. PubMed ID: 17266471 [TBL] [Abstract][Full Text] [Related]
14. [Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine]. Boot J; Rump BO; Boucher CA; Op de Coul EL; van Agtmael MA; van de Vijver DA; Burger DM; Fanoy EB Ned Tijdschr Geneeskd; 2013; 157(27):A6063. PubMed ID: 23838402 [TBL] [Abstract][Full Text] [Related]
16. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. Minnis AM; Gandham S; Richardson BA; Guddera V; Chen BA; Salata R; Nakabiito C; Hoesley C; Justman J; Soto-Torres L; Patterson K; Gomez K; Hendrix CW AIDS Behav; 2013 Feb; 17(2):737-47. PubMed ID: 23065145 [TBL] [Abstract][Full Text] [Related]
17. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. Denton PW; Othieno F; Martinez-Torres F; Zou W; Krisko JF; Fleming E; Zein S; Powell DA; Wahl A; Kwak YT; Welch BD; Kay MS; Payne DA; Gallay P; Appella E; Estes JD; Lu M; Garcia JV J Virol; 2011 Aug; 85(15):7582-93. PubMed ID: 21593172 [TBL] [Abstract][Full Text] [Related]